2 terminated, 1 completed, 1 withdrawn. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 2, Completed 1, Withdrawn 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Stage IIIC Melanoma: new trials by email Literature Review of Stage IIIC Melanoma trials Research Report on Stage IIIC Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma LN-144, Cyclophosphamide, Mesna - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 | Withdrawn | James Isaacs, MD | 2024-12-02 | 2025-06-05 | |
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis - Recurrent Melanoma, Recurrent Pancreatic Cancer | Phase 1 | Completed | Wake Forest University Health Sciences | 17 | 2014-12-01 | 2018-07-03 |
| Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery cabozantinib-s-malate, vemurafenib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 5 | 2013-05-01 | 2014-09-25 |
| Dinaciclib in Treating Patients With Stage III-IV Melanoma dinaciclib, pharmacological study, laboratory biomarker analysis - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 12 | 2009-09-01 | 2017-04-04 |
Melanoma (4) · Carcinoma, Renal Cell (1) · Pancreatic Neoplasms (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Neuroendocrine Tumors (4) · Nevi and Melanomas (4) · Skin Diseases (4) · Skin Neoplasms (4) · Skin and Connective Tissue Diseases (4) · Adenocarcinoma (1) · Carcinoma (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1)
Cyclophosphamide (1) · Interleukin-2 (1) · Mesna (1) · Vemurafenib (1) · aldesleukin (1) · cabozantinib (1) · dinaciclib (1) · fludarabine (1) · fludarabine phosphate (1) · lifileucel (1) · pembrolizumab (1)
National Cancer Institute (NCI) (2) · James Isaacs, MD (1) · Wake Forest University Health Sciences (1)
United States (3)
Frank Hodi (1) · James Isaacs, MD (1) · Jason Luke (1) · Pierre Triozzi (1)
P30CA006516 (2), U01CA062490 (2), P30CA012197 (1), UM1CA186709 (1)